HR Execs on the Move

EndoSound

www.endosound.com

 
Transforming the economics, usability, and accessibility of Endoscopic Ultrasound (EUS) for the benefit of patients, physicians, and payers.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.endosound.com
  • 4640, South Macadam Avenue
    Portland, OR USA 97239
  • Phone: 971.231.4791

Executives

Name Title Contact Details

Similar Companies

Alliance Protein Laboratories

Alliance Protein Laboratories is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DRX

DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evoke Pharmaceuticals

Evoke Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiel Laboratories

Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.